Practical applicability of landiolol, an ultra‐short‐acting β1‐selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction
Yuko Wada(Shiga University of Medical Science), Hisao Ogawa(Kumamoto University Hospital), Takeshi Aiba(National Cerebral and Cardiovascular Center), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Koji Miyamoto(National Cerebral and Cardiovascular Center), Minoru Horie(Nagahama City Hospital), Toshihisa Anzai(Hokkaido University), Hideki Itoh(Shiga University of Medical Science), Ikutaro Nakajima(National Cerebral and Cardiovascular Center), Kengo Kusano(Northwestern University), Takashi Noda(Tohoku University), Kohei Ishibashi(National Cerebral and Cardiovascular Center), Hideo Okamura(Kobe University), Mitsuru Wada(National Cerebral and Cardiovascular Center), Yasuo Sugano(keiyu Hospital), Yasuyuki Tsujita(Shiga University of Medical Science), Satoshi Yasuda(Tohoku University)
Cited by 43
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755